414 related articles for article (PubMed ID: 9607628)
1. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
3. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
[TBL] [Abstract][Full Text] [Related]
4. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
Böni R; Bantschapp O; Müller B; Burg G
Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
[TBL] [Abstract][Full Text] [Related]
5. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma.
Lazaris AC; Theodoropoulos GE; Aroni K; Saetta A; Davaris PS
Virchows Arch; 1995; 426(5):461-7. PubMed ID: 7633656
[TBL] [Abstract][Full Text] [Related]
7. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
8. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
9. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases.
Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Kim DK; Das Gupta TK
Surgery; 1995 Oct; 118(4):669-73; discussion 673-5. PubMed ID: 7570321
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer.
Lazaris AC; Theodoropoulos GE; Davaris PS; Panoussopoulos D; Nakopoulou L; Kittas C; Golematis BC
Dis Colon Rectum; 1995 Jul; 38(7):739-45. PubMed ID: 7607036
[TBL] [Abstract][Full Text] [Related]
12. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous malignant melanoma of the head and neck with intermediate tumor thickness: the role of elective lymph node dissection for clinical stage I].
Wenzel S; Sagowski C; Neuber K; Kehrl W; Metternich FU
Laryngorhinootologie; 2003 Jan; 82(1):19-24. PubMed ID: 12548460
[TBL] [Abstract][Full Text] [Related]
14. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.
Gershenwald JE; Mansfield PF; Lee JE; Ross MI
Ann Surg Oncol; 2000 Mar; 7(2):160-5. PubMed ID: 10761797
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
16. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355
[TBL] [Abstract][Full Text] [Related]
17. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.
Slingluff CL; Stidham KR; Ricci WM; Stanley WE; Seigler HF
Ann Surg; 1994 Feb; 219(2):120-30. PubMed ID: 8129482
[TBL] [Abstract][Full Text] [Related]
18. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence.
Mendenhall WM; Shaw C; Amdur RJ; Kirwan J; Morris CG; Werning JW
Am J Otolaryngol; 2013; 34(4):320-2. PubMed ID: 23375588
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.
White RR; Stanley WE; Johnson JL; Tyler DS; Seigler HF
Ann Surg; 2002 Jun; 235(6):879-87. PubMed ID: 12035046
[TBL] [Abstract][Full Text] [Related]
20. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma.
Brountzos EN; Panagiotou IE; Bafaloukos DI; Kelekis DA
Oncol Rep; 2003; 10(2):505-10. PubMed ID: 12579298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
